3rd Millennium Inc., of Cambridge, Mass., appointed Nathan Goodman senior vice president.
Ambion Inc., of Austin, Texas, named Peter Serpentino executive vice president and general manager of Ambion RNA Diagnostics, a new division.
Amgen Inc., of Thousand Oaks, Calif., named Donald Rice, president and CEO of UroGenesys Inc., to its board.
Biopure Corp., of Cambridge, Mass., named Michael Hensley to direct its regulatory and clinical affairs team.
ICOS Corp., of Bothell, Wash., added Michael Stewart as vice president of clinical affairs.
ILEX Oncology Inc., of San Antonio, named Jill Scoggins director of public relations.
Kosan Biosciences Inc., of Hayward, Calif., appointed Robert Judd director of program management, Andrew McFadden director of human resources and Michael Sherrill senior director of product development.
Oncotech Inc., of Irvine, Calif., added Khalil Sheibani as laboratory co-director and pathologist.
Oxigene Inc., of Watertown, Mass., appointed Frederick Driscoll president. Also, David Sherris was promoted to vice president of research and development.
Protein Design Labs Inc., of Fremont, Calif., added Jaisim Shah as vice president, marketing.
Structural Bioinformatics Inc., of San Diego, placed Michael Levitt, Minoru Kanehisa, Steve Bryant and John Reed on its scientific advisory board.
Targeted Genetics Corp., of Seattle, appointed Joseph Davie to its board.
The National Health Museum, of Washington, elected William Haseltine chairman of its board of trustees.
Xanthon Inc., of Research Triangle Park, N.C., appointed Eugene Johnston vice president, quality systems.